If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,332.00
Bid: 12,344.00
Ask: 12,346.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.016%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Friday preview: US Q1 GDP, RBS in focus

Thu, 25th Apr 2019 14:44

(Sharecast News) - Barring surprises, the market spotlight at the end of the week will continue to be on the States, where the Department of Commerce is expected to publish a preliminary reading on first quarter GDP (consensus: 1.8%). To take note of, the most recent estimate from the Federal Reserve bank of Atlanta's GDPNow model is for growth of 2.7%, which would be considerably higher than what is usually observed at the start of a year - due to statistical quirks - although it would follow the slowdown in growth seen at the tail end of 2018 to a pace of 2.6%.That piece of data will come alongside a final reading on the University of Michigan's closely-followed consumer confidence gauge covering the month of April.In the UK, the Confederation of British Industry will publish the results of its Distributive Trades survey for April.A raft of key economic indicators is also due out in Japan, including on core CPI in Tokyo during the month of April and for unemployment and industrial production in March.Straddling both continents, Asia and Europe, policymakers at Central Bank of Russia are due to decide on policy.No change in policy rates is anticipated, but any dovish shift in its forward guidance might see it join its peers in Canada, Japan, Sweden and Turkey since just last Wednesday.But whether in its case such a move towards a more dovish stance is yet advisable appears to still be open to debate. Turning to the UK corporate front, investors' focus will be on RBS. As with its peers over the course of the week, the latest update from the lender would afford insights into the impact that Brexit and negative interest rates in the Eurozone were having on the biggest British banks, said CMC Markets UK's Michael Hewson.But, added Hewson: "The slowdown in the UK economy in Q1 may well have affected loan demand across its various businesses."Also worth keeping an eye on will be any provisions for PPI and other non-performing items."For AstraZeneca, UBS's Michael Leuchten was anticipating total first quarter revenues of $5.4bn (consensus: $5.46bn) for a core operating profit of $1.5bn (consensus: $1.51bn).In particular, Leuchten said he would be watching the pharma giant's ability to generate cash, an important variable in his opinion given the need to finance the Daiichi deal, saying he expected it to be limited in the near-term.Progress on hitting its 2020 margin target of 30% would be another point of focus, as would the recent launches of Tagrisso, Lynparza and Imfinzi, given Astra's need to keep up top-line growth.In the background meanwhile, investors will be perusing quarterly results from US digital retail giant Amazon.com, which were due out after the close of trading on Wall Street on Thursday evening.Oil major Chevron's latest financials will also draw attention, with investors keen for the outfit's views on the outlook for oil prices, as well as regards the ongoing bidding war for Anadarko and its shale assets in the US Permian.Friday April 26INTERIM DIVIDEND PAYMENT DATEBioventix, Finsbury Food Group, Foresight Solar & Infrastructure VCT, Henderson EuroTrust, Oxford Technology 4 Venture Capital Trust, Smiths GroupQUARTERLY PAYMENT DATEAlpha Real Trust Ltd., Real Estate Investors, SQN Asset Finance Income Fund Limited, SQN Asset Finance Income Fund Limited 'C Shares', SQN Secured Income Fund , Standard Life Private Equity Trust, Value and Income TrustINTERNATIONAL ECONOMIC ANNOUNCEMENTSGDP (Preliminary) (US) (13:30)U. of Michigan Confidence (US) (15:00)GMSO'Key Group GDR (Reg S) (WI), Porta CommunicationsFINALSEU SupplySPECIAL DIVIDEND PAYMENT DATESherborne Investors (Guernsey) 'B' Limited, SSP GroupAGMSAlfa Financial Software Holdings , AstraZeneca, Capital Drilling Ltd. (DI), Co-operative Group Ltd Instal Repay Sub Nts 20/12/25, Greencoat UK Wind, Pearson, Public Joint Stock Company Severstal GDR (Reg S), ROS Agro GDR REG S, Rotork, SeniorTRADING ANNOUNCEMENTSWPPFINAL DIVIDEND PAYMENT DATEAmino Technologies, Glanbia, Globaldata, Somero Enterprises Inc. (DI)Q1AstraZeneca, Georgia Capital , Kcell Joint Stock Co GDR (Reg S), Royal Bank of Scotland Group
More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.